# Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery

* Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for enhanced breast cancer drug delivery
* 20nm Deciparticle(TM) achieves full bioavailability: Intravenous delivery of Everolimus (Afinitor(R)) maximizes tumor targeting and efficacy compared to 10% absorption with oral formulations
* Rapid IND platform accelerates pipeline: Strategic partnership with Medicilon supports up to 20 IND projects, shortening development timelines and enabling multiple Deciparticle(TM) drug candidates to reach clinical testing quickly

 Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores why particle size is critical to drug efficacy, how Oncotelic’s technology enhances tumor targeting, and how its rapid IND platform accelerates clinical development across multiple assets.

 Particle Size: The Key to Targeted Drug Delivery

 Delivering anticancer drugs effectively remains a central challenge in oncology. Conventional chemotherapy exposes healthy tissues to cytotoxic agents, producing severe side effects, while oral targeted therapies often fail to reach tumors at therapeutic concentrations. Nanomedicine offers a…

 Read More>>

 NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

 About BioMedWire

 BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

 BMW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.BioMedWire.com

 Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

 BioMedWireSan Francisco, CAwww.BioMedWire.com415.949.5050 OfficeEditor@BioMedWire.com

 BioMedWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/bmw/nanomedicines-next-leap-why-particle-size-matters-in-cancer-drug-delivery/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/oncotelic-s-20nm-nanoparticle-tech-boosts-cancer-drug-delivery-to-100/af5e61eda3196978b87eb450dc78e7a5) 


Pickup - [https://burstable.news/news](https://burstable.news/news/202510/259866-oncotelic-s-20nm-nanoparticle-technology-advances-to-human-trials-for-enhanced-breast-cancer-treatment)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202510/259874-oncotelic-therapeutics-inicia-ensayo-clinico-con-nanoparticulas-de-20nm-para-mejorar-tratamiento-del-cancer-de-mama)

Pickup - [https://estallarnoticias.com/](https://estallarnoticias.com//202510/259875-oncotelic-inicia-ensayo-clinico-con-nanoparticulas-de-20nm-para-mejorar-la-administracion-de-farmacos-contra-el-cancer-de-mama)

Pickup - [https://platzennachrichten.de/nachrichten](https://platzennachrichten.de/nachrichten/202510/259926-oncotelic-startet-phase-1-studie-mit-20nm-nanopartikel-technologie-fur-verbesserte-brustkrebsbehandlung)

Pickup - [https://actueclair.com](https://actueclair.com/202510/259916-oncotelic-lance-l-essai-clinique-sapu003-avec-sa-technologie-de-nanoparticules-de-20nm-pour-ameliorer-l-administration-des-medicaments-contre-le-cancer-du-sein)
 

 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/2510/21/numbrDRv.webp)